Two pivotal, 6-month studies—Study 1 (016) and Study 2 (settle)
In two randomized, 24-week, multicenter, double-blind, placebo-controlled trials, the efficacy and safety of XADAGO as add-on therapy to a stable dose of levodopa in PD patients experiencing motor fluctuations was evaluated.
Study 1 (016) and Study 2 (settle) efficacy outcomes
The Unified Parkinson’s Disease Rating Scale (UPDRS) is used to follow the longitudinal course of Parkinson’s disease. UPDRS III provides clinician-scored monitored motor evaluation.5